Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06172595
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-15
First Post:
2023-12-07
Brief Title:
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
Sponsor:
Singapore General Hospital
Organization:
Singapore General Hospital
Study Overview
Official Title:
18F-FET O-2-18FFluoroethyl-L-tyrosine PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FET PET in HGG
Brief Summary:
The goal of this clinical trial is to evaluate the performance characteristics of O-2-18Ffluoroethyl-L-tyrosine FET PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of 18FFET-PET in delineating disease The main questions it aims to answer are
whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression
whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PETCT of the brain in SGH
whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression
whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PETCT of the brain in SGH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None